A mixed year for deals and dollars left biotech execs hungry for a better 2025news2025-01-16T12:00:39+00:00January 16th, 2025|Endpoints News|
Australia’s BioCina and NovaCina join forces to make one CDMOnews2025-01-14T16:22:28+00:00January 14th, 2025|Endpoints News|
Daiichi Sankyo brings Glycotope antibody in-house for $132.5Mnews2025-01-14T12:07:47+00:00January 14th, 2025|Endpoints News|
Lilly to acquire cancer biotech Scorpion, which shares a co-founder with Loxonews2025-01-13T14:47:30+00:00January 13th, 2025|Endpoints News|
AstraZeneca, CRISPR tools supplier Synthego ink gene editing enzyme licensing dealnews2025-01-13T13:00:17+00:00January 13th, 2025|Endpoints News|
Updated: J&J to buy Intra-Cellular for $14.6B in latest neuroscience betnews2025-01-13T12:26:17+00:00January 13th, 2025|Endpoints News|
#JPM25: Day 1 at the JP Morgan Healthcare Conferencenews2025-01-13T12:00:19+00:00January 13th, 2025|Endpoints News|
Gilead taps into STAT6 space via $250M deal with Leo Pharmanews2025-01-13T11:58:44+00:00January 13th, 2025|Endpoints News|
GSK acquires IDRx and its rare cancer drug for $1B upfrontnews2025-01-13T07:00:57+00:00January 13th, 2025|Endpoints News|
Lantheus to buy Life Molecular Imaging for $350M, netting Alzheimer’s diagnosticnews2025-01-13T05:05:35+00:00January 13th, 2025|Endpoints News|
